Cargando…
COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896878/ https://www.ncbi.nlm.nih.gov/pubmed/36740090 http://dx.doi.org/10.1016/j.autrev.2023.103292 |
_version_ | 1784882140132933632 |
---|---|
author | Giannopoulou, Nefeli Gupta, Latika Andreoli, Laura Lini, Daniele Nikiphorou, Elena Aggarwal, Rohit Agarwal, Vikas Parodis, Ioannis |
author_facet | Giannopoulou, Nefeli Gupta, Latika Andreoli, Laura Lini, Daniele Nikiphorou, Elena Aggarwal, Rohit Agarwal, Vikas Parodis, Ioannis |
author_sort | Giannopoulou, Nefeli |
collection | PubMed |
description | COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the COVAD study, a global esurvey involving 157 collaborators from 106 countries. A total of 9201 complete responses were extracted. Among 6787 (73.8%) women, we identified 70 (1.1%) who were exposed to at least one COVID-19 vaccine dose during pregnancy, 11 with SLE. Delayed onset (>7 days) vaccine-related AEs were triangulated with disease activity, treatment changes due to flare after vaccination, and COVID-19 infections in vaccinated pregnant women. Health-related quality of life and physical function was recorded using PROMIS. Age of patients ranged from 28 to 39 years; 5/11 women were of Asian origin. None of these patients reported major vaccine AEs or change in the status of their autoimmune disease. Although minor AEs were common, they did not impair daily functioning, and the symptoms resolved after a median of 3 (IQR: 2.5–5.0) days. All patients reported good to excellent health status. No adverse pregnancy outcomes were reported. Importantly, none of the patients reported thrombotic events post-vaccination, which provides reassurance in a patient population with a high risk for cardiovascular comorbidity and thrombosis, especially in the presence of antiphospholipid antibodies or the antiphospholipid syndrome, a considerable portion of SLE patients. Our findings provide reassurance and can contribute to informed decisions regarding vaccination in patients with SLE and high-risk pregnancies due to their background autoimmune disease. The risk/benefit ratio of COVID-19 vaccination appears favourable, with vaccines both providing passive immunisation to the fetus and active immunisation to the mother with no signals of exacerbation of the mother's autoimmune disease. |
format | Online Article Text |
id | pubmed-9896878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98968782023-02-06 COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus Giannopoulou, Nefeli Gupta, Latika Andreoli, Laura Lini, Daniele Nikiphorou, Elena Aggarwal, Rohit Agarwal, Vikas Parodis, Ioannis Autoimmun Rev Article COVID-19 vaccination has been shown to be safe in patients with systemic lupus erythematosus (SLE), but data on vaccine-associated adverse events (AEs) during the antenatal and lactation period are scarce or lacking. We investigated COVID-19 vaccination-related AEs in pregnant SLE patients from the COVAD study, a global esurvey involving 157 collaborators from 106 countries. A total of 9201 complete responses were extracted. Among 6787 (73.8%) women, we identified 70 (1.1%) who were exposed to at least one COVID-19 vaccine dose during pregnancy, 11 with SLE. Delayed onset (>7 days) vaccine-related AEs were triangulated with disease activity, treatment changes due to flare after vaccination, and COVID-19 infections in vaccinated pregnant women. Health-related quality of life and physical function was recorded using PROMIS. Age of patients ranged from 28 to 39 years; 5/11 women were of Asian origin. None of these patients reported major vaccine AEs or change in the status of their autoimmune disease. Although minor AEs were common, they did not impair daily functioning, and the symptoms resolved after a median of 3 (IQR: 2.5–5.0) days. All patients reported good to excellent health status. No adverse pregnancy outcomes were reported. Importantly, none of the patients reported thrombotic events post-vaccination, which provides reassurance in a patient population with a high risk for cardiovascular comorbidity and thrombosis, especially in the presence of antiphospholipid antibodies or the antiphospholipid syndrome, a considerable portion of SLE patients. Our findings provide reassurance and can contribute to informed decisions regarding vaccination in patients with SLE and high-risk pregnancies due to their background autoimmune disease. The risk/benefit ratio of COVID-19 vaccination appears favourable, with vaccines both providing passive immunisation to the fetus and active immunisation to the mother with no signals of exacerbation of the mother's autoimmune disease. Elsevier B.V. 2023-04 2023-02-03 /pmc/articles/PMC9896878/ /pubmed/36740090 http://dx.doi.org/10.1016/j.autrev.2023.103292 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Giannopoulou, Nefeli Gupta, Latika Andreoli, Laura Lini, Daniele Nikiphorou, Elena Aggarwal, Rohit Agarwal, Vikas Parodis, Ioannis COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title | COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title_full | COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title_fullStr | COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title_full_unstemmed | COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title_short | COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
title_sort | covid-19 vaccine safety during pregnancy in women with systemic lupus erythematosus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896878/ https://www.ncbi.nlm.nih.gov/pubmed/36740090 http://dx.doi.org/10.1016/j.autrev.2023.103292 |
work_keys_str_mv | AT giannopoulounefeli covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT guptalatika covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT andreolilaura covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT linidaniele covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT nikiphorouelena covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT aggarwalrohit covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT agarwalvikas covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus AT parodisioannis covid19vaccinesafetyduringpregnancyinwomenwithsystemiclupuserythematosus |